Alnylam Pharmaceuticals Inc.ALNY
Close of Friday, October 23, 2026 · Alnylam Pharmaceuticals Inc. is trading below its Pivot, OnlyAlpha's long-term trend line.
Price
$224.03
vs its Pivot
-22.7%
OnlyAlpha Score
54
Trend
Below its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| -10.2% | -43.7% | -51.8% | +10.7% | +1.4% |
No dividend in the last 12 months.
Who runs and owns it
In these funds
IBB · 2.21%IYH · 0.49%IQQ · 0.13%IYY · 0.04%
Suppliers, customers and partners
ALNY sells to
| Regeneron | RNAi collaboration; royalties to Alnylam |
| Novartis | Leqvio (inclisiran) via MDCO agreement |
| Sanofi | Qfitlia tiered royalties |
Partners and deals
| Roche (Genentech) | zilebesiran; 50/50 profit/loss |
| Blackstone | $1.0B for 50% of royalties |
From the companies' own annual reports filed with the SEC.
Healthcare · Biotech
Get ALNY in your free daily emailAfter every close: whether ALNY is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track ALNY free → Full Stock check
Track ALNY free → Full Stock check